Search

Your search keyword '"Valori, V.M."' showing total 20 results
Start Over Author "Valori, V.M."
20 results on '"Valori, V.M."'

2. Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel

Author

Pasculli, B., Barbano, R., Rendina, M., Fontana, A., Copetti, M., Mazza, T., Valori, V.M., Morritti, M., Maiello, E., Graziano, P., Murgo, R., Fazio, V.M., Esteller, M., Parrella, P., and Universitat Autònoma de Barcelona

Subjects
0301 basic medicine, Oncology, Micro RNAs, medicine.medical_treatment, lcsh:Medicine, Docetaxel, 0302 clinical medicine, Breast cancer, Antineoplastic Combined Chemotherapy Protocols, Breast, Prospective Studies, lcsh:Science, Prospective cohort study, Mastectomy, Aged, 80 and over, Adjuvant treatment of cancer, Multidisciplinary, Middle Aged, Gene Expression Regulation, Neoplastic, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, miRNAs, Disease Progression, Female, MiRNAs, Epirubicin, medicine.drug, Tractament adjuvant del càncer, Adult, medicine.medical_specialty, Cyclophosphamide, Breast surgery, Breast Neoplasms, Predictive markers, Article, Càncer de mama, 03 medical and health sciences, Cell Line, Tumor, Internal medicine, Biomarkers, Tumor, medicine, Humans, Aged, Retrospective Studies, Chemotherapy, business.industry, lcsh:R, Computational Biology, Retrospective cohort study, medicine.disease, MicroRNAs, 030104 developmental biology, Drug Resistance, Neoplasm, lcsh:Q, business, Follow-Up Studies
Abstract

MicroRNA-210-3p is the most prominent hypoxia regulated microRNA, and it has been found significantly overexpressed in different human cancers. We performed the expression analysis of miR-210-3p in a retrospective cohort of breast cancer patients with a median follow-up of 76 months (n = 283). An association between higher levels of miR-210-3p and risk of disease progression (HR: 2.13, 95%CI: 1.33-3.39, P = 0.002) was found in the subgroup of patients treated with Epirubicin and Cyclophosphamide followed by Docetaxel. Moreover, a cut off value of 20.966 established by ROC curve analyses allowed to discriminate patients who developed distant metastases with an accuracy of 85% at 3- (AUC: 0.870, 95%CI: 0.690-1.000) and 83% at 5-years follow up (AUC: 0.832, 95%CI: 0.656–1.000). Whereas the accuracy in discriminating patients who died for the disease was of 79.6% at both 5- (AUC: 0.804, 95%CI: 0.517–1.000) and 10-years (AUC: 0.804. 95%CI: 0.517–1.000) follow-up. In silico analysis of miR-210-3p and Docetaxel targets provided evidence for a putative molecular cross-talk involving microtubule regulation, drug efflux metabolism and oxidative stress response. Overall, our data point to the miR-210-3p involvement in the response to therapeutic regimens including Docetaxel in sequential therapy with anthracyclines, suggesting it may represent a predictive biomarker in breast cancer patients.

Published
2019

3. Oral Anticancer Therapy Project: clinical utility of a specific home care nursing program

Author

Cirillo, M., primary, Carlucci, L., additional, Baldini, E., additional, Sacco, C., additional, Zagonel, V., additional, Leo, S., additional, Llimpe, F.L. Rojas, additional, Tonini, G., additional, Marialuisa, M., additional, Alfredo, T., additional, Farci, D., additional, Sava, T., additional, Zaninelli, M., additional, Valori, V.M., additional, Quaranta, A., additional, Carrozza, F., additional, Micheloni, B., additional, Marchetti, F., additional, Lunardi, G., additional, Zamboni, S., additional, Pinto, C., additional, and Gori, S., additional

Published
2016
Full Text
View/download PDF

4. Evaluation of pre-analytical procedures for the detection of BRAF V600 mutations in melanoma patients: comparison between Sanger sequencing and Competitive allele-specific TaqMan PCR (Cast-PCR)

Author

Barbano, R., primary, Pasculli, B., additional, Coco, M., additional, Fontana, A., additional, Copetti, M., additional, Rendina, M., additional, Valori, V.M., additional, Graziano, P., additional, Maiello, E., additional, Fazio, V.M., additional, and Parrella, P., additional

Published
2016
Full Text
View/download PDF

11. 35 DNA DOUBLE STRANDS BREAK REPAIR GENES EXPRESSION ANALYSIS REVEAL RAD51 AS A NEW POTENTIAL BIOMARKER IN BREAST CANCER.

Author

Barbano, R., primary, Copetti, M., additional, Perrone, G., additional, Muscarella, L.A., additional, Balsamo, T., additional, Poeta, M.L., additional, Valori, V.M., additional, Latiano, T., additional, Maiello, E., additional, Carella, M., additional, Pellegrini, F., additional, Murgo, R., additional, Muda, A. Onetti, additional, Fazio, V.M., additional, and Parrella, P., additional

Published
2010
Full Text
View/download PDF

13. Experience of 170 cases of ductal carcinoma in ‘ (DCIS)

Author

D’Addetta, C., primary, Latiano, T.P., additional, Piano, A., additional, Valori, V.M., additional, Morritti, M., additional, Cilenti, G., additional, Murgo, R., additional, Bisceglia, M., additional, Parisi, S., additional, Valvano, M.R., additional, and Maiello, E., additional

Published
2008
Full Text
View/download PDF

16. Hepatic Intra-Arterial Chemotherapy (HIAC) of High Dose Mitomycin and Epirubicin Combined with Caval Chemofiltration Versus Prolonged Low Doses in Liver Metastases from Colorectal Cancer: a Prospective Randomized Clinical Study

Author

Fiorentini, G., primary, Poddie, D.B., additional, Cantore, M., additional, Rossi, S., additional, Tumolo, S., additional, Dentico, P., additional, Bernardeschi, P., additional, Guadagni, S., additional, Rossi, G., additional, Valori, V.M., additional, and De Simone, M., additional

Published
2004
Full Text
View/download PDF

18. Human Antithrombin III Heterogeneity: A Study by Isoelectrofocusing and Crossed Immunoelectrofocusing

Author

Leone, G., Valori, V.M., Cotumaccio, R., and Massi, G.

Abstract

Isoelectrofocusing was carried out in the LKB Multiphor apparatus with pH 4–6.5 carrier ampholines using polyacrylamide gel slabs. Specimens of purified antithrombin III (AT-III), normal plasma and serum were isoelectrofocused. Microheterogeneity was shown by three preparations of purified AT; the protein was separated in at least six bands, three large bands were located in the pH range 4.9–5.2, one intermediate band at pH 4.85, other thinner bands were located in the pH range 4.55–4.80. The microheterogeneity of AT-III was confirmed in purified preparations as well as in plasma and in serum by crossed immunoelectrofocusing. The pattern of purified preparations, normal plasma and serum were very similar; only minor, quantitative differences were noticed. Plasma from a patient with congenital AT-III deficiency showed an abnormal pattern.

Published
1983
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results